Elekta AB (publ) a un dividende annuel de 0.25 par action, avec un rendement de 0.00%. Le dividende est payé semestriellement et la dernière date d'ex-dividende était le Sep 8, 2025.
Rendement en dividend
Dividende annuel
Date ex-dividende
0.00%
$0.25
Sep 8, 2025
Fréquence des paiements
Taux de distribution
Semestriellement
0.00%
Historique des dividendes
Date ex-dividende
Montant en espèces
Date de registre
Date de paiement
Sep 8, 2025
$0.1286
Sep 8, 2025
Sep 26, 2025
Mar 7, 2025
$0.1187
Mar 7, 2025
Mar 27, 2025
Sep 9, 2024
$0.116
Sep 9, 2024
Sep 27, 2024
Feb 26, 2024
$0.1157
Feb 27, 2024
Mar 18, 2024
Aug 25, 2023
$0.1094
Aug 28, 2023
Sep 15, 2023
Feb 24, 2023
$0.1137
Feb 27, 2023
Mar 17, 2023
Graphiques des dividendes
EKTAY Dividendes
EKTAY Croissance des dividendes (variation annuelle)
Follow-Up Questions
Quel est le dividende actuel payé par Elekta AB (publ) et son dividende annuel ?
Quel est le ratio de distribution de dividendes de Elekta AB (publ) ?
Quelle est la date ex-dividende pour EKTAY ?
À quelle fréquence Elekta AB (publ) verse-t-elle des dividendes ?
Statistiques clés
Clôture préc.
$6.57
Prix d'ouverture
$6.93
Plage de la journée
$6.8 - $6.93
Plage de 52 semaines
$4.35 - $6.93
Volume
200
Volume moyen
5.6K
BPA (TTM)
0.08
Rendement en dividend
--
Capitalisation boursière
$2.4B
Qu’est-ce que EKTAY ?
Elekta AB is a medical technology company, which engages in the provision of clinical solutions for the treatment of cancers and brain disorders. The company is headquartered in Stockholm, Stockholm and currently employs 4,484 full-time employees. The firm offers and develops systems for radiation therapy and radio-surgery, as well as software systems that enhance workflow efficiency throughout the entire spectrum of cancer care. Elekta AB (publ) develops clinical treatment solutions for radiation therapy and radiosurgery, as well as work flow-enhancing software systems, across the spectrum of cancer care. The firm provides clinical solutions for image guided radiation therapy and stereotactic radiosurgery, giving oncologists and neurosurgeons an unmatched capability to treat tumors and functional targets with ultra-high precision while sparing healthy tissue.